Tuesday - September 22, 2026
Novartis receives positive CHMP opinion for Cosentyx in polymyalgia rheumatica (PMR)
September 18, 2026
BASEL, Switzerland, Sept. 18 [Category: BizPharmaceuticals] -- Novartis, a pharmaceutical company, posted the following news release:

* * *

Novartis receives positive CHMP opinion for Cosentyx(r) in polymyalgia rheumatica (PMR)

*

* If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids1

* Recommendation based . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products